Deprescribing BZRAs taken for insomnia: A review and key messages from practice guidelines

2019-02-01
Justin Y. Lee, Barbara Farrell, Anne Marie Holbrook

Full article

A PDF of the full version of the article can be accessed free of charge through the website of Polish Archives of Internal Medicine.

Abstract

Long-term benzodiazepine receptor agonist (BZRA) use for insomnia is common and highly prevalent in adults in all care settings. Evidence syntheses suggest that the therapeutic benefits of benzodiazepines for insomnia are marginal and very short term. On the harm side, BZRAs are associated with daytime sedation and confusion. Long-term use increases the risk of falls, fractures, cognitive impairment, and motor vehicle accidents.

An evidence-based clinical practice guideline has been developed to assist with deprescribing BZRAs. This review highlights the rationale for deprescribing BZRAs used for insomnia and summarizes key messages for clinicians from the new BZRA deprescribing guideline and their supporting evidence.

See also

We would love to hear from you

  • Do you have any comments?
  • Have you found a mistake?
  • Would you like to suggest a feature?

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.